EXIS
With $35M Bioprinting Investment Prellis Biologics Takes on New CEO
Organ bioprinting startup Prellis Biologics raised $35 million in a Series C round and plans to use the fresh capital to expand its proprietary, first-in-class human immune system-based drug discovery…
Featured
Prellis Biologics Secures $14.5M for Bioprinted Lymph Node
Prellis Biologics secured a $14.5 million series B round lead by Celesta Capital with existing shareholders Khosla Ventures. Prellis has an Externalized Immune System (EXIS) platform which allows researchers to discover…
